Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical WR 279,396 for Cutaneous Leishmaniasis in Tunisia
NCT00703924Phase 2Completed
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Mar 2003
- Primary completion
- Nov 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in cutaneous leishmaniasis (CL) comparing WR 279,396 with Placebo (2 arms). Primary endpoints: Complete Clinical Response at Day 180 and Safety of WR 279,396 at 180 days. Started Mar 2003; status: completed.
02
Drugs
WR 279,396
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT00703924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00703924.